Loading...
Market
What will be the public reaction to Sarepta Therapeutics' gene therapy following the censorship incident by December 31, 2024?
2
Resolution / Starting Odds
Mostly positive • 25%
Mostly negative • 25%
Mixed • 25%
Neutral • 25%
Public opinion polls, social media sentiment analysis, or patient advocacy group statements
Story
Sarepta ($SRPT) Faces Backlash for Censoring Critical Duchenne Advocacy Video
Jul 29, 2024, 12:18 PM
Sarepta Therapeutics ($SRPT) has come under scrutiny for demanding a prominent Duchenne muscular dystrophy patient advocacy organization censor a video that contained pointed criticism of its new gene therapy. The video, which was critical of Sarepta's approach and its impact on patients, was subsequently taken down. This incident, reported by STAT, has raised questions about the relationship between drugmakers and patient advocacy groups. The news has sparked discussions about the influence pharmaceutical companies exert over advocacy organizations and the potential implications for patient care and transparency.
View original story
Similar markets
Positive • 25%
Negative • 25%
Mixed • 25%
Indifferent • 25%
Mostly positive • 25%
Mostly negative • 25%
Mixed • 25%
Indifferent • 25%
Yes • 50%
No • 50%
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%
Yes • 50%
No • 50%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Positive • 33%
Neutral • 33%
Negative • 34%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Indifferent • 25%
Increased vaccine hesitancy • 25%
No change in public opinion • 25%
Increased trust in vaccines • 25%
Mixed reactions • 25%